Risks, benefits of long-term drug therapy for osteoporosis reviewed

Health Problems

(HealthDay)—Long-term osteoporosis drug therapy (ODT) reduces fracture risk in women but may increase risk for rare adverse events, and research gaps surround use of long-term drug therapies for osteoporotic fracture prevention, according to a review and position paper published online April 23 in the Annals of Internal Medicine. Howard A. Fink, M.D., M.P.H., from the University of Minnesota in Minneapolis, […]

Continue reading »

Discovery of enhanced bone growth could lead to new treatments for osteoporosis

Health Problems

UCLA and UC San Francisco life scientists have discovered a dramatic pattern of bone growth in female mice—research that could potentially lead to stronger bone density in women and new treatments for osteoporosis in older women. The researchers found that blocking a particular set of signals from a small number of neurons in the brain causes female, but not male, […]

Continue reading »

Osteoporosis drug may benefit heart health

Health Problems

The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. The association was seen for up to 10 years after fracture. In the study, patients newly diagnosed with hip fracture from 2005 through 2013 were followed until late 2016. […]

Continue reading »

In Europe, CHMP missed an opportunity for osteoporosis patients at high risk of fracture

Health Problems

Experts from the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) regret the recent decision by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) to reject the marketing application for abaloparatide, a potential new treatment option for postmenopausal women at high risk of […]

Continue reading »